As seen in case #2, CPZ treatment effectively inhibited the growth of AML samples with MT-RTKs and statistically significant differences were observed in 6/8 cases with FLT3 ITD and 1/1 case with KIT D816V. This evidence concerns the gene KIT and acute myeloid leukemia.